WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker released the following statement on the announcement by congressional leadership of a funding agreement that includes full repeal of the medical device excise tax. The agreement is expected to be passed this week by Congress and signed into law by President Trump:
WASHINGTON, D.C. – In an op-ed published today in Morning Consult, AdvaMed President and CEO Scott Whitaker urges Congress to act before the medical device excise tax comes back into effect Jan. 1.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement today from President and CEO Scott Whitaker regarding the U.S. Senate’s confirmation of Dr. Stephen Hahn to serve as the new FDA Commissioner:
“Dr. Hahn is an excellent choice to lead FDA, and we congratulate him on his swift and overwhelming bipartisan confirmation. During the confirmation process, Dr. Hahn demonstrated his deep understanding of the agency’s mission to protect and promote the public health and the role of innovation in improving patient care. His background as a physician, researcher and administrator will serve the American people well at this vital agency. We look forward to working with him on behalf of the patients our industry serves.”
WASHINGTON, D.C. – In today’s Wall Street Journal, the editorial board wrote that Congress “should stop a return of the destructive” medical device excise tax scheduled to go into effect on Jan. 1.
WASHINGTON, D.C. – More than half of medical device company employees expect reinstatement of the medical device excise tax in 2020 to lead both to job losses and cuts to research and development programs, according to a new survey by a top industry and business news publisher, SmartBrief.
Washington, D.C. – The Advanced Medical Technology Association (AdvaMed) today issued the following statement from President and CEO Scott Whitaker on the newly upgraded United States-Mexico-Canada Agreement (USMCA):
WASHINGTON, D.C. – The Medical Alley Association yesterday released a survey of its membership demonstrating that if the medical device tax is reinstated on Jan. 1, 2020, 83 percent of medtech companies will decrease R&D spending, 67 percent will delay or forego planned hiring, and 47 percent will delay plans to physically expand their business.
WASHINGTON, D.C. – More than 1,000 medical technology companies started after the device tax was last in effect (from 2013-15) will pay the excise tax for the first time in January if Congress fails to repeal or delay the tax, according to an AdvaMed analysis of the industry.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) released the following statement from President and CEO of AdvaMed Scott Whitaker on today's November jobs report by the U.S. Dept. of Labor:
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker on the introduction of legislation in the U.S. House by Reps. Suzan DelBene (D-Wash.), Jackie Walorski (R-Ind.), Tony Cardenas (D-Calif.), Gus Bilirakis (R-Fla.), Roger Marshall (R-Kan.), and Terri Sewell (D-Ala.) to streamline Medicare coverage and reimbursement processes for innovative medical technologies: